Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Clinical trial NCT03913923 · UNKNOWN

Trial details

NCT number: NCT03913923
Sponsor: Biocad
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Melanoma Metastatic

Start date: 2019-07-01
Primary completion: 2023-07-01
Enrollment: 117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.